Background
Methods
Registered protocol
Inclusion criteria
Outcome measures and follow-up assessment
Search strategy
Study selection and data extraction
Internal validity
Data synthesis
Quality of evidence
Results
Study selection
General characteristics
Study | Setting | Population | Intervention | Comparison | Outcome |
---|---|---|---|---|---|
Brenner 2018 [23] Prospective observational | Resuscitation in Trauma and Acute Care Surgery (AORTA) study was approved by the American Association for the Surgery | Adult trauma and acute care surgery (age ≥ 18) patients undergoing aortic occlusion (AO) in the acute phases after injury were enrolled Blunt trauma was common (58.6% of which 83% REBOA group and 48.5% RT) ISS: mean 38.2 (SD:18.9) | REBOA (n = 83) Unclear modality of intervention (full/partial)* | RT (n = 202) | In-hospital mortality, complication, units packed red blood cells, units fresh frozen plasma, health-related quality of life (neurologic outcomes: Glasgow Coma Outcomes Score) |
Aso 2017 [22] Retrospective cohort study | Data from a national inpatient database in Japan | Trauma patients with uncontrolled haemorrhagic shock (n = 259); penetrating thoracic injuries were excluded Blunt trauma (100%) ISS: missing information | REBOA (n = 191) Unclear modality of intervention (full/partial) | RT (n = 68) | In-hospital mortality, ventilator-free days (VFDs), intensive care unit (ICU)-free days, total amount of fluid infusion within 1 day after admission (mL), total amount of transfusion within 1 day after admission (mL), total hospitalization costs |
Abe 2016 [21] Retrospective cohort study | Japan Trauma Data Bank (JTDB) nationwide trauma registry | Trauma patients (n = 903) Blunt trauma was common (838/895; 93.6%) ISS: mean 34 (SD:25); mean 34 (SD:20) | REBOA (n = 636) Unclear modality of intervention (full/partial) | Resuscitative open aortic cross-clamping (RT) (n = 267) | In-hospital mortality, ED mortality, blood transfusion |
DuBose 2016 [24] Prospective observational | Multicentre data from Trauma and Acute Care Surgery registry (8 American College of Surgeons level I centres) | Adult trauma and acute care surgery (age ≥ 18) patients undergoing aortic occlusion (AO) in the acute phases after injury (n = 114) Blunt trauma (62.3%) ISS: median 31.0(IQR: 30); median 31.5 (IQR: 22) | REBOA (n = 46) Unclear modality of intervention (full/partial) | AO (n = 68) | Haemodynamic stability, Improvement in haemodynamic red blood cell requirements, in-hospital mortality, ED mortality, Complications, health-related quality of life (neurologic outcomes: Glasgow Coma Outcomes Score) |
Moore 2015 [29] Retrospective cohort study | Trauma registry from two Level 1 trauma Centres (Texas and Maryland-Baltimore) | Trauma patients in NCTH (n = 96) Blunt trauma (44.4% RT; 66.7% REBOA) ISS: median 34 (IQR:27–59); median 28 (IQR:17–43) | REBOA (n = 24) Unclear modality of intervention (full/partial) | RT (n = 72) | In-hospital mortality, ED mortality |
Matsumara 2017* Retrospective cohort study | DIRECT-IABO Registry has been conducted by the Academic Committee in DIRECT in Japan | Trauma patients with refractory haemorrhagic shock Blunt trauma (96%) ISS: median 36 (IQR: 28–50); 44 (IQR: 38–59) | REBOA (n = 76) Partial occlusion (70% of participants) * | RT + REBOA group (n = 30) | In-hospital mortality |
Nori 2015 [31] Retrospective cohort study | Japan Trauma Data Bank | Critically uncontrolled haemorrhagic shock limited to blunt trauma patients. Blunt trauma (100%) ISS: mean 32.4 (SD:16.4) | REBOA (n = 351) Unclear modality of intervention (full/partial) | Control group (n = 1456) | In-hospital mortality, health-related quality of life (neurologic outcomes: Glasgow Coma Outcomes Score) |
García 2020 [25] Retrospective cohort study | Clinical records at Fundación Valle del Lili University hospital in Cali, Colombia level-I trauma centre from Colombia | Patients with torso trauma who underwent surgical intervention for haemorrhage control excluded blunt trauma. Penetrating trauma (100%) ISS: median 25 (IQR: 16–25) | REBOA (n = 28) Partial occlusion* | Control group (n = 317) | In-hospital mortality, PRBCs A in first 6 h , Plasma A in first 6 h, platelet A in first 6 h, Cryo A in first 6 h , Crystalloids in first 24 h, Thoracic damage control, Abdominal damage control, complications |
Inoue 2016 [26] Retrospective cohort study | Japan Trauma Data Bank | Patients with severe torso trauma Blunt trauma (93.8%) ISS: median 35 (IQR: 25–50); median 36 (IQR: 25–50) | REBOA (n = 625) Unclear modality of intervention* | Control group (n = 625) | In-hospital mortality, ED mortality |
Joseph 2019 [27] Retrospective case-control study | ACSTQIP database and identified all patients who received REBOA within 1 h of admission | Trauma patients after REBOA placement Blunt trauma (95%) ISS: median 28 (IQR:17–35); median 29 (IQR: 18–38) | REBOA (n = 140) Unclear modality of intervention* | Control group (n = 280) | In-hospital mortality, ED mortality, transfusion requirements at 4 h and 24 h after injury, in-hospital complications (deep venous thrombosis, pulmonary embolism, stroke, myocardial infarction, extremity compartment syndrome, health-related quality of life (neurologic outcomes: Glasgow Coma Outcomes Score) |
Yamamoto 2019 [30] Retrospective cohort study | Japan Trauma Data Bank | Severely injured patients Blunt trauma (96% REBOA; 94% controls) ISS: mean 35 (SD: 13); 33 (SD: 11) | REBOA (n = 117) | Control group (n = 117) | Survival at 28 days, a composite of in-hospital death, transfusion in number of patients |
Overall mortality
Overall mortality | REBOA | Control | Time/setting | OR adjusted/matched | Description of adjustment | ||||
---|---|---|---|---|---|---|---|---|---|
N | Tot | % | n | Tot | % | ||||
Aso 2017 [22] (REBOA vs RT) | 90 | 191 | 47 | 48 | 68 | 70.6 | Time frame not reported | Hazard ratio = 0.94; 95%CI = 0.60–1.48§ OR 0.821; 95% CI 0.306–1.234 | Adjusted propensity score |
Brenner 2018 [23] (REBOA vs RT) | 75 | 83 | 90.3 | 197 | 202 | 97.5 | 24 h | OR = 0.24; 95% CI 0.08–0.75 | None |
Abe 2016 [21] (REBOA vs RT) | 405 | 636 | 63.7 | 210 | 267 | 78.7 | Time frame not reported ED | OR 0.261 95%CI 0.130–0.523 Pair-matched n = 304 | Adjusted propensity score |
DuBose 2016 [24] (REBOA vs RT) | 33 | 46 | 71.7 | 57 | 68 | 83.8 | ED 24 h | OR = 0.263; 95% CI = 0.043–1.609 | not reported (regression) |
Moore 2015 [29] (REBOA vs RT) | 15 | 24 | 62.5 | 65 | 72 | 90.3 | time frame not reported ED | None | None |
Matsumara 2017 (REBOA vs REBOA+RT) | 41 | 76 | 53.9 | 27 | 30 | 90.0 | 24 h 1 month At discharge | None | None |
Nori 2015* [31] (REBOA vs no-REBOA) | 259 | 351 | 73.8 | 709 | 1456 | 48.7 | Time frame not reported | OR = 2.97; 95% CI = 2.29–3.84 Pairs matched 1:5 | Adjusted propensity score |
García 2020 [25] (REBOA vs no-REBOA) | 5 | 28 | 17.8 | 48 | 317 | 15.1 | Time frame not reported | OR = 0.20; 95%CI 0.05–0.77 | Adjusted propensity score |
Inoue 2016* [26] (REBOA vs no-REBOA) | 386 | 625 | 61.7 | 283 | 625 | 45.3 | Time frame not reported ED | OR = 1.95, 95% CI 1.56–2.45 | Adjusted propensity score ° |
Joseph 2019* [27] (REBOA vs no-REBOA) | 50 | 140 | 35.7 | 53 | 280 | 18.9 | ED overall | OR= 2.38; 95% CI= 1.51–3.76 | Adjusted propensity score |
Yamamoto 2019* [30] (REBOA vs no-REBOA) | 64 | 117 | 54.7 | 79 | 117 | 67.5 | Time frame not reported | OR = 0.58; 95% CI = 0.34–0.99 | Adjusted propensity score |
Volume of infused blood components
Autore | Outcome | Units | REBOA | Controla | p value |
---|---|---|---|---|---|
Cryoprecipitate | |||||
Dubose 2016 [24] | Cryoprecipitate 24 h | Median (IQR) | 1 (11) | 0 (1) | 0.14 |
Garcia 2020 [25] | Cryoprecipitate 6 h | Median (IQR) | 6.5 (0–10) | 0 (0–0) | 0.21 |
Crystalloids | |||||
Garcia 2020 [25] | Crystalloids 24 h millilitres | Median (IQR) | 4649 (3290–6329) | 4420 (2705–6350) | 0.13 |
Dubose 2016 [24] | Crystalloids 24 h litres | Median (IQR) | 4 (5) | 3 (5) | 0.12 |
Plasma | |||||
Joseph 2019 [27] | Plasma 24 h | Median (IQR) | 9 (6–20) | 10 (7–20) | 0.17 |
Brenner 2018 [23] | Plasma 24 h | Median (IQR) | 9 (16) | 4 (9) | 0.11 |
DuBose 2016 [24] | Plasma 24 h | Median (IQR) | 14.5 (18) | 6 (18) | < 0.001 |
Joseph 2019 [27] | Plasma 4 h | Median (IQR) | 3 (2–5) | 3 (2–6) | 0.001 |
Garcia 2020 [25] | Plasma 6 h | Median (IQR) | 4 (2.5–6) | 0 (0–4) | < 0.001 |
Platelets | |||||
Joseph 2019 [27] | Platelets 24 h | Median (IQR) | 7 (3–13) | 8 (3–12) | < 0.001 |
DuBose 2016 [24] | Platelets 24 h | Median (IQR) | 5.5 (12) | 1.5 (11) | 0.5 |
Joseph 2019 [27] | Platelets 4 h | Median (IQR) | 4 (3–9) | 4 (3–8) | 0.05 |
Garcia 2020 [25] | Platelets 6 h | Median (IQR) | 0.5 (0–6) | 0 (0–0) | 0.05 |
PRBCs | |||||
Joseph 2019 [27] | PRBCs 24 h | Median (IQR) | 9 (5–20) | 10 (4–21) | 0.3988 |
Brenner 2018 [23] | PRBCs 24 h | Median (IQR) | 10 (21) | 7.8 (10) | 0.654 |
DuBose 2016 [24] | PRBCs 24 h | Median (IQR) | 20.5 (18) | 13.5 (18) | 0.343 |
Joseph 2019 [27] | PRBCs 4 h | Median (IQR) | 6 (3–8) | 7 (3–9) | 0.872 |
Garcia 2020 [25] | PRBCs 6 h | Median (IQR) | 5 (3–9) | 2 (0–4) | 0.149 |
Total amount of transfusion | |||||
Aso 2016 [22] | Total amount of transfusion within 1 d after admission: average (SD), mL | media (sd) | 2.396 (1.872) | 2.820 (2.782) | 0.697 |
Transfusion in number of patients | |||||
Abe 2016 [21] | Transfusion in number of patients | n (%) | 542 (85%) | 197 (74%) | 0.001 |
Yamamoto 2019 [30] | Transfusion in number of patients | n (%) | 111 (95%) | 113 (97%) | < 0.001 |